% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Kremer:892447,
      author       = {Kremer, Thomas and Taylor, Kirsten I. and Siebourg-Polster,
                      Juliane and Gerken, Thomas and Staempfli, Andreas and Czech,
                      Christian and Dukart, Juergen and Galasko, Douglas and
                      Foroud, Tatiana and Chahine, Lana M. and Coffey, Christopher
                      S. and Simuni, Tanya and Weintraub, Daniel and Seibyl, John
                      and Poston, Kathleen L. and Toga, Arthur W. and Tanner,
                      Caroline M. and Marek, Kenneth and Hutten, Samantha J. and
                      Dziadek, Sebastian and Trenkwalder, Claudia and Pagano,
                      Gennaro and Mollenhauer, Brit},
      title        = {{L}ongitudinal {A}nalysis of {M}ultiple {N}eurotransmitter
                      {M}etabolites in {C}erebrospinal {F}luid in {E}arly
                      {P}arkinson's {D}isease},
      journal      = {Movement disorders},
      volume       = {36},
      number       = {8},
      issn         = {1531-8257},
      address      = {New York, NY},
      publisher    = {Wiley},
      reportid     = {FZJ-2021-02085},
      pages        = {1972-1978},
      year         = {2021},
      abstract     = {Background: Cerebrospinal fluid (CSF) levels of monoamine
                      metabolites may represent biomarkers of Parkinson's disease
                      (PD).Objective: The aim of this study was quantification of
                      multiple metabolites in CSF from PD versus healthy control
                      subjects (HCs), including longitudinal analysis.Methods:
                      Absolute levels of multiple monoamine metabolites in CSF
                      were quantified by liquid chromatography coupled with tandem
                      mass spectrometry from 161 individuals with early PD and 115
                      HCs from the Parkinson's Progression Marker Initiative and
                      de novo PD (DeNoPA) studies.Results: Baseline levels of
                      homovanillic acid (HVA) and 3,4-dihydroxyphenylacetic acid
                      (DOPAC) were lower in individuals with PD compared with HCs.
                      HVA levels correlated with Movement Disorder Society Unified
                      Parkinson's Disease Rating Scale total scores (P < 0.01).
                      Both HVA/dopamine and DOPAC/dopamine levels correlated with
                      caudate nucleus and raw DOPAC with putamen dopamine
                      transporter single-photon emission computed tomography
                      uptake ratios (P < 0.01). No metabolite changed over 2 years
                      in drug-naive individuals, but some changed on starting
                      levodopa treatment.Conclusions: HVA and DOPAC CSF levels
                      mirrored nigrostriatal pathway damage, confirming the
                      central role of dopaminergic degeneration in early PD. ©
                      2021 The Authors. Movement Disorders published by Wiley
                      Periodicals LLC on behalf of International Parkinson and
                      Movement Disorder Society.Keywords: CSF; Parkinson's
                      disease; biomarker; catecholamine; homovanillic acid;
                      monoamine metabolites; neurotransmitter.},
      cin          = {INM-7},
      ddc          = {610},
      cid          = {I:(DE-Juel1)INM-7-20090406},
      pnm          = {525 - Decoding Brain Organization and Dysfunction
                      (POF4-525)},
      pid          = {G:(DE-HGF)POF4-525},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:33942926},
      UT           = {WOS:000646650300001},
      doi          = {10.1002/mds.28608},
      url          = {https://juser.fz-juelich.de/record/892447},
}